Introduction {#Sec1}
============

The t(8;21)(q22;q22) occurs in about 5% of all acute myeloid leukemias (AML) and in 10% of cases of AML with FAB-M2 morphology \[[@CR1]\]. The Runt domain transcription factor *RUNX1 (AML1)* is essential for differentiation of hematopoietic stem cells. The t(8;21) generates the *RUNX1-RUNX1T1 (AML1-ETO)* fusion protein that acts as transcriptional repressor and inhibits the expression of *AML1* responsive genes. This in turn causes a block in hematopoietic stem cell differentiation which in conjunction with additional genetic events leads to leukemic transformation \[[@CR2], [@CR3]\]. Studies have shown that t(8;21) by itself is incapable of leukemogenesis and additional genetic events are necessary for development of AML \[[@CR4], [@CR5]\]. Among these additional genetic changes that cooperate with *RUNX1-RUNX1T1* fusion to cause AML, activating *KIT* mutations appear to be the most common. Data suggest that activating mutations in the receptor tyrosine kinases such as *KIT* play a role in the development of overt t(8;21)AML \[[@CR5]--[@CR8]\].

Systemic mastocytosis (SM) occurs due to an activating *KIT* mutation in a hematopoietic progenitor that leads to abnormal proliferation and accumulation of neoplastic mast cells in the bone marrow and other organs. In a subset of SM termed systemic mastocytosis with associated hematological non-mast cell disease (SM-AHNMD) in the current WHO classification, SM coexists with hematologic malignancies that are usually of myeloid origin \[[@CR1], [@CR9]\]. SM-AHNMD comprises 20% of all cases of SM and the most common associated hematologic malignancies are acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myeloproliferative disorders, and myelodysplastic/myeloproliferative syndromes such as chronic myelomonocytic leukemia \[[@CR10]--[@CR13]\].

In previous studies, the frequency of *KIT* mutations involving exon 17 as represented by a single amino acid substitution at D816 in patients with t(8;21)(q22;q22) AML have ranged from 12% to 24.2% \[[@CR14]--[@CR17]\]. Most common mutations described were at D816 and involved the Asp to Val substitution (D816V) \[[@CR14]--[@CR17]\]. Other substitutions included D816H, D816Y, and those at N822 including N822K and N822T \[[@CR14]--[@CR17]\]. Despite the fact that activating exon 17 *KIT* mutations are not uncommon in t(8;21) AML, a review of published literature suggests that SM associated with t(8;21) AML is exceedingly rare. Data on such cases are limited and largely confined to a handful of single case reports. We report our experience with SM associated with t(8;21)(q22;q22) AML and review the current literature on this rare entity.

Materials and methods {#Sec2}
=====================

Patients with t(8;21) AML who also met WHO criteria for SM either at initial diagnosis or at relapse were identified from the databases of our institutions. Additional cases were identified by PubMed search of the English language literature as well as from the reference list of the reported cases \[[@CR17]--[@CR20]\]. Immunohistochemistry for CD117, tryptase, and CD25 staining was performed using standard techniques. Polymerase chain reaction (PCR) amplification and direct sequencing of the exon 17 of the *KIT* gene were performed by methods previously described \[[@CR9]\]. Briefly, genomic DNA was isolated from bone marrow specimens using a QiAmp kit (Qiagen, Valencia, CA, USA). The codon 816-containing region of the *KIT* gene was amplified using the primers: 5′-TGT GAA CAT CAT TCA AGG CGT AC-3′ (forward) and 5′-ACT CAG CCT GTT TCT GGG AAA CTC-3′ (reverse). PCR conditions were each cycle of 30 s at 93°C, 1 min at 50°C, and 5 min at 72°C for a total of 40 cycles. The resulting 322-bp product was purified from a 2.5% agarose gel using a gel extraction kit (Qiagen) and directly sequenced. On case 3, fluorescence in situ hybridization (FISH) analysis for t(8;21)(q22;q22) on morphologically identified bone marrow mast cells (target FISH) was performed. Briefly, Wright-Giemsa stained bone marrow aspirate smears were scanned with a Bioview Duet Image Analyzer (Bioview, Rehovot, Israel) to identify mast cells for FISH. Following destaining with Carnoy's fixative and digestion with pepsin, slides were co-denatured with t(8;21) probe (Vysis, Downer's Grove, IL, USA). Slides were counterstained with DAPI and analyzed on a BioView Duet Image analyzer. Details of the target FISH technique were described previously \[[@CR21]\].

Results {#Sec3}
=======

The clinical and pathologic features of the patients are summarized in Table [1](#Tab1){ref-type="table"}. Of the ten patients who are included in this report, cases 1 through 6 were treated at our institutions and four additional cases (cases 7--10) were identified from the literature \[[@CR17]--[@CR20]\]. Cases 1, 2, and 3 of this series were included in previous reports \[[@CR9], [@CR21]\]. Table 1Clinical and pathological features of SM with t(8;21) AMLNo.RefAge/sexClinical presentationBone marrow morphologyImmunophenotypeCytogenetics*KIT* Exon 17Initial treatmentClinical courseBlastsMast cells1Case 1 \[[@CR9]\]26/MAML with multilineage dysplasia, WBC---35,400/µL 44% blastsHypercellular with Multilineage Dysplasia, 43% myeloblastsCD13, CD33, CD11b, CD34, HLA-DR, CD56 CD7dim CD19 negativeTryptase46XY t(8;21)(q22;q22)D816HIdarubicin + cytarabine followed by mitoxantrone + etoposideInduction failure, died of progressive leukemiaIncreased mast cells distributed randomly and perivascularly, indented nuclei, normal granularity2Case 2 \[[@CR9]\]43/FAML with multilineage dysplasiaHypercellularity with multilineage dysplasia, 31% myeloblastsCD13, CD33, CD34, CD117Tryptase46XX t(8;21)(q22;q22)NDDaunorubicin + cytarabine followed by HiDAC for 3 cyclesRemission achieved after induction. Relapsed with myeloid sarcoma 1 year after diagnosis. Underwent HSCT but died of relapsed disease 3 years laterIncreased mast cells scattered and perivascular, normal morphology. Mast cell infiltrate prominent after treatment3Case 3 \[[@CR21]\]51/FFAB-M2 AML40% myeloblasts, increased mast cells (30% of cellularity)CD13, CD33CD, CD38, CD117, HLA-DR, MPOTrytase, CD2, CD2546X t(8;21)(q22;q22) del(9)(q12;q22) Monosomy XD816VDaunorubicin + cytarabine followed by 2 cycles of HiDACAML in complete remission after induction chemotherapy. Persistence of mast cellsProminent infiltrate of clustered, spindle-shaped mast cells (80--90% of cellularity) after leukemia remissionAllogeneic HSCT from matched sibling after conditioning with TBI and etoposide. AML in remission 4 years after SCT. Persistence but gradual decline of recipient mast cells \[carrying t (8;21)\] 1 year after HSCT4Case 454/F1 year history of metastatic breast cancer treated with anthracycline-based chemotherapy. Therapy-related AML. WBC 58,200/µL, 96% blastsComplete replacement of diagnosis bone marrow by myeloblasts. No increase in mast cellsCD34, CD33dim, CD117dim, HLA-DR, CD56, CD19 (dim)CD25, CD11746XX t(8;21)(q22;q22)D816V A814SDaunorubicin + cytarabine consolidation with HiDAC 3 cyclesMorphologic remission after induction. Bone marrow after consolidation showed relapse. Died of relapsed AML 8 months after diagnosis70% cellular post-consolidation marrow with 27% blasts and numerous mast cells with indented twisted nuclei and normal granularity5Case 529/FFAB-M2 AML. WBC---45,400/µLHypercellular, 76% myeloblasts with increased mast cells, occasional spindled mast cells presentCD13, CD33 (dim), CD56 (bright), CD34, CD117, CD19 (dim)CD2, CD25, Tryptase45XY t(8;21)(q22;q22), del9(q22) \[[@CR20]\]D816YIdarubicin + cytarabineInduction failure. Died of progressive leukemia 1 year after diagnosis6Case 646/MFAB-M2 AML WBC 92,600/µL 82% blasts95% cellularity, 60% myeloblasts, increased mast cells in perivascular and paratrabecular aggregates comprising about 20% of marrow cellularity. Pronounced mast cell infiltrate after treatmentCD13, CD56 CD15^a^, CD34, CD38 CD19^a^ CD117, HLA-DRCD11746XX t(8;21)(q22;q22) del(9)(q22q34)D816^b^Idarubicin + cytarabine + ImatinibInduction failure. Awaiting stem cell transplant7Wong et al. \[[@CR17]\]51/FFAB-M2 AML WBC---2,800/µL 12% blasts60% myeloblasts and increased mast cells positive for chloro-acetate esteraseMPO Chloroacetate esteraseChloroacetate esteraset(8;21)(q22;q22) Monosomy 21NADanorubicin, thioguanine, cytarabine followed by cytarabine and mitoxantroneMorphologic remission of leukemia after chemotherapy. Persistence of bone marrow mastocytosis and development of hepatosplenomegaly from mast cell infiltration. Died of disease 6 months after diagnosis8Escribano et al. \[[@CR18]\]67/FFAB-M2 AML WBC-25,000/µL 71% blastsAspirate revealed 59% myeloblasts, no dysplasia. Increased atypical mast cells, oval nuclei, hypogranular cytoplasm and abnormal granularityCD13, 33, 117 CD7^a^, CD19^a^Tryptase CD2, 25, 117Normal conventional cytogenetics (46XX), FISH: t(8;21)(q22;q22)D816V not detected ^c^Idarubicin + cytarabine 2 cyclesMorphologic remission of AML after 2 cycles of induction. Persistent bone marrow mastocytosis. Relapsed 1 year after diagnosis and died of disease in second relapse 2 years after diagnosis9Bernd et al. \[[@CR19]\]48/MFAB-M2 AMLHypercellularity, sheets of myeloblastsMyeloperoxidae and chloroacetate esteraseCD25, CD117, tryptase46XY t(8;21;12)(q22;q22;q24)D816VIdarubicin + cytarabine for 3 cycles, HiDAC one cycleMorphologic remission of AML after one cycle of chemotherapy. AML remained in remission 20 months after diagnosis. Bone marrow mastocytosis persisted for 18 monthsLoosely scattered mast cells at diagnosis. Mastocytosis prominent after leukemic remission10Nagai et al. \[[@CR20]\]31/FWBC---18,600/µL 69% blastsHypercellularity, 54% myeloblasts, multifocal dense infiltrates of mast cells at diagnosis. Mastocytosis pronounced after induction chemotherapyPositive: CD13, CD34, CD56, CD117, HLA-DRCD25, CD11746XX, t(8;21)(q22;q22) del9 (q22;q34)D816YIdarubicin + cytarabine followed by mitoxantrone + cytarabineInduction failure after 2 cycles of chemotherapyAllogeneic HSCT from matched sibling after conditioning with TBI and cyclophosphamidePersistent bone marrow mastocytosis but remission of leukemia over 1 year after HSCT*ND* not detected, *FAB* French American British, *WBC* white blood cell, *HiDAC* high dose cytarabine, *HSCT* hematopoietic stem cell transplantation, *TBI* total body irradiation, *NA* data not available^a^Denotes expression on subset of blasts^b^Exact mutation not analyzed^c^Not known if other KIT mutations were examined

The patients ranged in age from 26 to 67 years and included three males and seven females. None of the patients had urtricaria pigmentosa or other evidence of extramedullary mast cell involvement except for one published case that showed hepatic infiltration with mast cells after AML induction therapy \[[@CR17]\]. Symptoms related to mast cell mediator release were not reported in any of the patients. All cases had morphologic and immunophenotypic features of AML with maturation (FAB-M2). Leucocytosis was present at diagnosis in six of seven patients in whom initial blood counts were available. Patient 4 had metastatic breast cancer and had undergone anthracycline-containing combination chemotherapy. She developed SM with t(8;21)(q22;q22) AML 1 year after initiation of chemotherapy. In nine of the ten cases, increased bone marrow mast cells were noted at the time of AML diagnosis In case 4, SM was diagnosed following three cycles of consolidation chemotherapy for AML. In that case, the bone marrow biopsies at diagnosis were reevaluated, but failed to demonstrate coexisting SM. An activating exon 17 *KIT* mutation was detected in seven of nine cases in whom this data is available. Three patients had D816V, two had D816Y, and one carried the D816H mutation. In one case (case 6) the exact mutation was not analyzed while another (case 4) carried an A814S mutation in addition to D816V. It is noteworthy that four of the ten cases had chromosome 9q deletion as an additional cytogenetic abnormality. Of the eight cases where immunophenotype data on the myeloblasts was available by flow cytometry, four of eight cases reported dim expression of CD19 and five of eight cases showed CD56 expression (Table [1](#Tab1){ref-type="table"}). Bone marrow pathology of a representative case is shown in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1**a** Pretreatment bone marrow aspirate (case 3) showing predominantly myeloblasts admixed with rare mast cells. Note the hypergranular cytoplasm within the mast cells (Wright-Giemsa, ×500). **b** Day 14 post-treatment bone marrow aspirate (case 3) with prominent mast cell infiltrate (Wright-Giemsa, ×200). **c** Immunohistochemistry for tryptase (case 3) highlights the mast cell infiltrate (×200). **d** Mast cells show expression of CD25 (case 3), a characteristic feature of neoplastic mast cells (×200)

All patients were initially treated with AML induction chemotherapy that contained an anthracycline and cytarabine. Four of the ten patients failed to achieve a morphologic remission after induction chemotherapy. Six of the ten patients have died of progressive or relapsed leukemia and one patient remains with active disease awaiting allogeneic HSCT. The two long-term survivors (cases 3 and 10) in this report had both undergone allogeneic HSCT from matched siblings after radiation-based high-dose conditioning. In these two patients, recipient-derived bone marrow mast cells were detected up to a year after HSCT, but the leukemia remained in durable remission.

Discussion {#Sec4}
==========

In this report, we have summarized our experience and reviewed the published literature on SM that coexists with t(8;21)(q22;q22) AML. *KIT* mutations are the most common additional genetic abnormality in t(8;21) AML and range in their incidence from 26% to 47% in various reports \[[@CR22]--[@CR24]\]. However, among the t(8;21) AML with *KIT* mutations, the number of cases that have concurrent SM appears to be extremely rare. Hence, it appears that specific genetic events in addition to activating *KIT* mutations and t(8;21) are required for development of mastocytosis. Although it can be postulated that these additional genetic events may promote mast cell differentiation from leukemic progenitors, the nature of these additional genetic aberrations remains unknown.

Studies examining the relationship between mast cells and leukemic blasts have shown that the neoplastic mast cells of SM associated with t(8;21) carry the *RUNX1-RUNX1T1* translocation, thereby proving their derivation from the leukemic clone. This was demonstrated in case 3 of this series by target FISH, the details of which have been published elsewhere \[[@CR21]\]. Similar findings were noted in another published case that is included in the current series (case 10, Nagai et al.) where *KIT* mutation as well as *RUNX1-RUNX1T1* translocation was detected in recipient-derived clonal mast cells that persisted after allogeneic HSCT \[[@CR20]\]. In both these cases, the recipient-derived mast cells gradually declined and the AML remained in remission. It is unclear if this phenomenon represents gradual apoptosis of these mast cells or progressive elimination of leukemic progenitors due to graft-versus-leukemia effect.

We sought to examine if there were other distinct cytogenetic or pathologic features that were associated with SM and t(8;21) AML. Deletion of chromosome 9q was an additional cytogenetic finding in four of the ten cases. Del (9q) has been previously reported as part of a complex phenotype in another case of t(8;21) positive myelomastocytic leukemia (AML with increased bone marrow mast cells not meeting criteria for SM) \[[@CR26]\]. In addition, del (9q) is the most common additional cytogenetic abnormality in t(8;21) AML and has been reported in 7--14% of pediatric cases and 9.7% of adult cases \[[@CR27]\]. In comparison, del (9q) appears to be more frequent in t(8;21) with associated SM, suggesting that this deletion may play a role in the pathogenesis of SM. Recently, *TLE1* and *TLE4* have been identified as critical genes in the commonly deleted 9q region in t(8;21) AML \[[@CR28]\]. In vitro experiments using Kasumi-1 cell line showed that these genes behave as tumor suppressors and knockdown of *TLE1* or *TLE4* increased the rate of cell division of the *AML1-ETO* expressing Kasumi-1 cell line while forced expression of either caused apoptosis and cell death \[[@CR28]\].

The precise incidence of SM coexisting with t(8;21) AML is unknown. In previous reports, authors have cautioned that in some cases of AML with coexisting SM, the diagnosis of SM maybe missed on the initial bone marrow evaluation due to the excess numbers of blasts which mask the underlying mast cells and the tendency of mast cells to localize within stroma of bone marrow particles in aspirate smears \[[@CR9]\]. The bone marrow mast cell infiltrate appears to become more evident when the leukemic blasts decrease after therapy as was seen in this report (Fig. [1](#Fig1){ref-type="fig"}b). This prominence of the mast cell infiltrate after chemotherapy may also be due to the poor sensitivity of the mast cells to leukemia chemotherapy as evidenced by their persistence even after high-dose chemotherapy conditioning for allogeneic HSCT \[[@CR20]\]. Infiltration of extramedullary tissues with mast cells, as well as symptoms due to mast cell mediator release, appear to be distinctly uncommon in cases of SM associated with t(8;21) AML. This may be due to the lack of functionality of these neoplastic MC as a result of the leukemic aberrations they carry.

AML with t(8;21)(q22;q22) as the sole cytogenetic abnormality in general have a favorable outcome when treated with consolidation regimens containing high-dose cytarabine \[[@CR29], [@CR30]\]; however, studies have shown that only 50% of t(8;21) AML patients are alive at 5 years \[[@CR27]\]. D816 *KIT* mutations were detected in 10.5% of patients with t(8;21) AML in one study \[[@CR17]\]. The presence of *KIT* mutations (D816 and others) may explain the poor prognosis of a subset of t(8;21) patients as activating exon 17 *KIT* mutations have now been shown to be a major adverse prognostic factor for event-free and overall survival in t(8;21) AML \[[@CR14]--[@CR17]\] and a predictor of higher relapse risk \[[@CR15]\]. The number of patients with mutant *KIT* who had SM in addition has not been reported in any of these studies, which may be an indicator of its extreme rarity. Interestingly, in previous studies it has been reported that 91--100% of t(8;21) AML patients with *KIT* mutations achieved complete remission after chemotherapy \[[@CR15], [@CR25]\]. However, in our current series induction failure occurred in four of ten patients. This observation again re-emphasizes the fact that SM associated with AML has a grave prognosis.

It is worth noting that of the ten patients (Table [1](#Tab1){ref-type="table"}) only two patients achieved a durable remission of AML. Both of these patients had undergone allogeneic HSCT. One of our patients (case 3) is in continuous remission 4 years after allogeneic HSCT. Sperr et al. have reported a patient with myelomastocytic leukemia and t(8;21) AML who relapsed after a reduced intensity HSCT, but achieved a lasting remission following high-dose conditioning and a second HSCT from the same donor, thereby suggesting that conditioning intensity may be important \[[@CR26]\]. Although data are very limited, the dismal results with conventional chemotherapy suggests that allogeneic HSCT should be an early consideration in SM associated with t(8;21) AML in patients who are suitable candidates. The D816V *KIT* mutation is resistant to the tyrosine kinase inhibitor imatinib \[[@CR31]\]. Dasatinib, to which *KIT* D816V is sensitive, may have a role in the therapy of these cases as evidenced by in vitro data as well as its in vivo activity of this drug in recent reports of SM, including a patient with SM-AML \[[@CR32]--[@CR34]\]. Other tyrosine kinase inhibitors like midostaurin (PKC 412) and nilotinib (AMN 107)) that are capable of inhibiting activating *KIT* D816V may also have potential in the treatment of t(8;21) AML that carry this mutation \[[@CR35], [@CR36]\].

In conclusion, SM associated with t(8;21) AML is extremely rare and carries a dismal prognosis. During evaluation of t(8;21)(q22;q22) AML, care should be taken to look for coexisting SM in the initial and subsequent bone marrow specimens since the mast cell infiltrate may be subtle and easily overlooked. This will help identify a subset of t(8;21) AML patients with a particularly poor prognosis.
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